Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: The Circulatory Risk in Communities Study (CIRCS)

Imano, Hironori; Noda, Hiroyuki; Kitamura, Akihiko; Sato, Shinichi; Kiyama, Masahiko; Sankai, Tomoko; Ohira, Tetsuya; Nakamura, Masakazu; Yamagishi, Kazumasa; Ikeda, Ai; Satō, Takashi; Iso, Hiroyasu

doi:10.1016/j.ypmed.2011.02.019

Cited by 81 publications

(59 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in Japan, epidemiological studies, such as the NIPPON DATA80 2) , Suita 24) , JALS 25) , CIRCS 1) , Hiroshima/Nagasaki 7)…”

Section: Hyper-ldl Cholesterolemiamentioning

confidence: 99%

“…The CIRCS, an epidemiological study recently conducted in Japan 1) , showed that the incidence of CAD in subjects with an LDL-C level of 80 to 99 mg/ dL, 100 to 119 mg/dL, 120 to 139 mg/dL and ≥ 140 mg/dL is 1.4-, 1.7-, 2.2-and 2.8-fold higher, respectively, than that observed in subjects with a LDL-C level of ＜80 mg/dL. In the presence of multiple risk factors, the incidence of and mortality from CAD also increase in Japanese individuals.…”

Section: Hyper-ldl Cholesterolemiamentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Criteria for Dyslipidemia

Teramoto

Sasaki

Ishibashi

et al. 2013

JAT

130

View full text Add to dashboard Cite

“…In addition, in Japan, epidemiological studies, such as the NIPPON DATA80 2) , Suita 24) , JALS 25) , CIRCS 1) , Hiroshima/Nagasaki 7)…”

Section: Hyper-ldl Cholesterolemiamentioning

confidence: 99%

Section: Hyper-ldl Cholesterolemiamentioning

confidence: 99%

Diagnostic Criteria for Dyslipidemia

Teramoto

Sasaki

Ishibashi

et al. 2013

JAT

130

View full text Add to dashboard Cite

“…Large-scale cohort studies have shown that the incidence of cardiovascular disease (CVD) increases with greater low-density lipoprotein cholesterol (LDLC) levels [1][2][3] . Furthermore, the efficacy of LDLClowering therapy via HMG-CoA reductase inhibitors …”

Section: Introductionmentioning

confidence: 99%

A Proposal for the Optimal Management Target for Serum Non-High-Density Lipoprotein Cholesterol Level in Low-Risk Japanese Workers

Saiki

Otsuka

Kato

et al. 2016

JAT

View full text Add to dashboard Cite

, the use of statins for the primary prevention of CVD events have resulted in a reduced risk of up to approximately 20%. These findings indicate the existence of substantial residual risk. Research has indicated remnant lipoproteins, i.e., intermediate metabolites of chylomicron and very-low-density lipoprotein, as major sources of IntroductionLarge-scale cohort studies have shown that the incidence of cardiovascular disease (CVD) increases with greater low-density lipoprotein cholesterol (LDLC) levels [1][2][3] . Furthermore, the efficacy of LDLClowering therapy via HMG-CoA reductase inhibitors

show abstract

“…Dyslipidemia is an important risk factor for CVD, and epidemiologic studies have shown that higher low-density lipoprotein (LDL) cholesterol 1) and non-high-density lipoprotein (HDL) cholesterol levels 2) and lower HDL between the incidence of CVD and dyslipidemia, achieved BP and the lipid levels in patients with no history of CVD using data obtained from the OMEGA study. The relationship between the comprehensive control of four CVD risk factors (BP, LDL cholesterol, HbA1c and smoking) and the incidence of CVD was also analyzed.…”

Section: Introductionmentioning

confidence: 99%

Lipid and Blood Pressure Control for the Prevention of Cardiovascular Disease in Hypertensive Patients: A Subanalysis of the OMEGA Study

Teramoto

Kawamori

Miyazaki

et al. 2015

J Atheroscler Thromb

View full text Add to dashboard Cite

Aim:The aim of this analysis was to investigate the relationships between dyslipidemia, achieved blood pressure (BP) values and the lipid levels, as well as the control of four cardiovascular risk factors (BP, low-density lipoprotein: LDL cholesterol, hemoglobin A1c: HbA1c and smoking) and the incidence of cardiovascular disease (CVD), in Japanese patients receiving antihypertensive therapy. Methods: A total of 13,052 patients with no history of CVD were included in this subanalysis of the prospective observational OMEGA study in Japanese hypertensive patients treated with olmesartan. Multivariable Cox regression models were used to evaluate the relationship with the risk of CVD. Results: The incidence of CVD during the 36-month study period was 5.59/1,000 patient-years among the patients with dyslipidemia (n 6,297) and 5.57/1,000 patient-years among the patients without dyslipidemia (n 6,755), with no significant differences between the two groups. Higher achieved BP values tended to be associated with an increased CVD risk in both the patients with and without dyslipidemia. In addition, the risk of CVD tended to be higher in the patients with an achieved LDL cholesterol level of ≥ 120 mg/dL than in those with an LDL level of 120 mg/dL (trend p 0.0005) and in the patients with an achieved high-density lipoprotein cholesterol level of 60 mg/dL than in those with an HDL level of ≥ 60 mg/dL (trend p 0.0017). Furthermore, the risk of CVD was higher among the patients with fewer controlled risk factors than among those with control of all four risk factors (trend p 0.0001). Conclusions: In order to prevent CVD in olmesartan-treated hypertensive patients with no history of CVD, it is important to control both the lipid and BP levels and aim for comprehensive risk factor control.J Atheroscler Thromb, 2015; 22:62-75.

show abstract

Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: The Circulatory Risk in Communities Study (CIRCS)

Cited by 81 publications

References 19 publications

Diagnostic Criteria for Dyslipidemia

Diagnostic Criteria for Dyslipidemia

A Proposal for the Optimal Management Target for Serum Non-High-Density Lipoprotein Cholesterol Level in Low-Risk Japanese Workers

Lipid and Blood Pressure Control for the Prevention of Cardiovascular Disease in Hypertensive Patients: A Subanalysis of the OMEGA Study

Contact Info

Product

Resources

About